There are many obstetric, medial, and surgical disorders that share many of the clinical and laboratory findings of patients with severe pre-eclampsia-eclampsia. Imitators of severe pre-eclampsia-eclampsia are life-threatening emergencies that can develop during pregnancy or in the postpartum period. These conditions are associated with high maternal and perinatal mortalities and morbidities, and survivors may face long-term sequelae. The pathophysiologic abnormalities in many of these disorders include vasospasm, platelet activation or destruction, microvascular thrombosis, endothelial cell dysfunction, and reduced tissue perfusion. Some of these disorders include acute fatty liver of pregnancy, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, acute exacerbation of systemic lupus erythematosus, and disseminated herpes simplex and sepsis syndromes. Differential diagnosis may be difficult due to the overlap of several clinical and laboratory findings of these syndrome. It is important that the clinician make the accurate diagnosis when possible because the management and complications from these syndromes may be different. Because of the rarity of these conditions during pregnancy and postpartum, the available literature includes only case reports and case series describing these syndromes. This review focuses on diagnosis, management, and counseling of women who develop these syndromes based on results of recent studies and my own clinical experience. 
S
everal microangiopathic disorders that are encountered during pregnancy provide physicians with a formidable, if not impossible, diagnostic challenge. Severe pre-eclampsia with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome and many other obstetric and medical or surgical conditions produce similar clinical presentations and laboratory study results to pre-eclampsia. 1 In addition, pre-eclampsia is not infrequently superimposed upon one of these disorders, further confounding an already difficult differential diagnosis. Because of the remarkably similar clinical and laboratory findings of these disease processes, even the most experienced physician will face a difficult diagnostic challenge. 1 Therefore, an effort should be made to attempt to identify an accurate diagnosis given the fact that management strategies and outcome may differ among these conditions. In this review, I will describe the pathogenesis, differential diagnosis, and management of the medical conditions described in the box below.
Acute Fatty Liver of Pregnancy
Acute fatty liver of pregnancy (AFLP) is a rare but potentially fatal complication of the third trimester. The incidence of this disorder ranges from 1 in 10,000 to 1 in 15,000 deliveries. The incidence is probably lower than that because the reported rates are usually from large referral centers, which tend to overestimate the true incidence. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] It has been suggested that AFLP is more common in nulliparous women as well as in those with multifetal gestation. [1] [2] [3] [4] [5] [6] [7] 9 The clinical onset of symptoms ranges from 27 to 40 weeks, with an average of 36 weeks' gestation 6 ; however, cases have been reported in the second trimester. 11, 2 In some cases, the first onset of signs/symptoms may be in the postpartum period. 2, 9 The patient typically presents with a 1-to 2-week history of malaise, anorexia, nausea, vomiting, midepigastric or right upper quadrant pain, headache, or jaundice. The urine will have a bright yellow appearance ( Fig. 1) . Rarely, the patient may present with hepatic encephalopathy. 13 Symptoms of preterm labor or lack of fetal movement may be the presenting complaint in some of these patients. 2, 3 In about 15-20%, the patient might not present with any of the above symptoms. [2] [3] [4] [5] Physical examination reveals an ill-appearing patient with jaundice. Some patients will have a low-grade fever. Other findings may include hypertension and even proteinuria and ascites and bleeding from severe coagulopathy. Because of these findings, the diagnosis may be initially confused with pre-eclampsia. 1, 2, 6 Neurologic findings may range from normal to lethargy, agitation, confusion, and even coma. 8, 9, 13, 14 
Laboratory Findings
The complete blood count usually reveals hemoconcentration, elevated white blood count, and platelet count that is initially normal but may be low. [1] [2] [3] [4] [5] [6] Coagulation findings reveal low fibrinogen, prolonged prothrombin time (PT), and low levels of antithrombin. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] These abnormalities are related to reduced production of these factors by the liver and are consistent with disseminated intravascular coagulopathy (DIC). In contrast, the DIC seen in severe pre-eclampsia and abruptio placentae is due to abnormal consumption. 15 Serum electrolytes will reveal evidence of metabolic acidosis with elevated creatinine and uric acid values. Blood sugar may be normal but is usually low in the postpartum period. [1] [2] [3] [4] [5] [6] 8, 9, 13 Blood sugars may also be elevated in association with secondary pancreatitis. 1, 8 Liver enzymes, such as AST, ALT, alkaline phosphatase, and bilirubin, will be elevated. The increase in bilirubin is mainly of the conjugated form, with levels usually exceeding 5 mg/dL. Ammonia levels are also increased, particularly in late stage of the disease. Amylase and lipase values may be elevated in the presence of concomitant pancreatitis. 1, 8 Hepatitis profile for A, B, and C will be negative.
Ultrasonography of the liver may reveal the presence of increased echogenicity in severe cases; however, it is less sensitive than computed tomography (CT) and magnetic resonance imaging (MRI). [16] [17] [18] [19] [20] In addition, quantitation of liver density by ultrasound is subjective and operator-dependent. CT scan of the liver may show decrease or diffuse attenuation in the liver. However, none of these techniques are sufficiently sensitive to exclude a diagnosis of AFLP. 2, 20 Liver biopsy is the gold standard for confirming the diagnosis of AFLP. Histopathologic findings in AFLP reveal swollen, pale hepatocytes with central nuclei. 21 The diagnosis can be made only on a frozen section liver biopsy with special stains for fat, such as oiled red (O). 1, 4 Plans to perform this stain should be made before the biopsy procedure because it is not possible to be performed once the tissue has been submitted to routine paraffin blocks. Liver biopsy should be performed only after correction of coagulopathy. However, this is rarely used in clinical practice, and the diagnosis is usually made based on clinical and laboratory findings. [1] [2] [3] [4] [5] [6] [7] [8] [9] In addition to the other conditions listed in Box I, the differential diagnosis of AFLP should include idiopathic cholestasis of pregnancy, Budd-Chiari syndrome, adult-onset Reye's syndrome, and drug-induced hepatic toxicity (acetaminophen overdose, tetracycline-induced toxicity, anticonvulsant drugs hypersensitivity, and methyldopa hepatitis). 1, 4, 21 
Maternal and Perinatal Complications
AFLP is associated with an increased risk of maternal mortality and morbidities. In the past, the rate of maternal death was close to 70%; however, recent data indicate a mortality rate of Ͻ10%, but maternal complications remain high. Table 1 describes maternal complications in recent series of AFLP. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 14, 22, 23 Recently, Davidson and coworkers reported on three women with triplet gestation who had AFLP proven by liver biopsy who survived. They suggested that women with triplets are at increased risk for AFLP because of potential for increased production of fatty acid metabolites by three fetuses. It has been suggested that the improved maternal survival in recent years was related to the supportive care and aggressive management of serious maternal complications by a multidisciplinary group of physicians from various specialties. [2] [3] [4] [5] [6] [7] [8] [9] Recently, Knight, and coworkers 11 reported a prospective national study of AFLP in the UK. The participants included 57 women with AFLP diagnosed mostly by clinical criteria; 55 had abdominal ultrasound scan, but only 12 (27%) had either ascites and/or abnormal liver findings. Forty-two (74%) were diagnosed antepartum and 15 (26%) postpartum (within 4 days of delivery). In general, most of these patients had a biochemical diagnosis of AFLP (mild prolongation of PT, PTT, normal platelets), only 8 (16%) had acute renal failure, and 4 (7%) required ventilatory support. There was only 1 maternal death (1.8%) in a patient who received a liver transplant. 14 Both perinatal mortality and morbidities are increased in patients of AFLP. [2] [3] [4] [5] [6] [7] [8] [9] 20 The perinatal mortality among 160 births (142 pregnancies) in recent case series was 13.1%. 9, 22 In addition, neonatal morbidity remains high because of the high rate of preterm delivery (74%) among reported cases. The average gestational age at delivery was 34 weeks (range, 25-42 weeks). [2] [3] [4] [5] [6] [7] [8] [9] 22 In the study by Knight and coworkers, 11 the perinatal mortality was 10.4% among 67 infants (6 stillbirths and 1 neonatal death).
Management of AFLP
The clinical course of women with AFLP is usually characterized by progressive and sometimes sudden deterioration in maternal and fetal conditions. 9 Therefore, patients in whom AFLP is considered require hospitalization in a labor and delivery unit. Fetal heart rate monitoring and/or performing of a biophysical profile should be performed concurrently with maternal evaluation. Evidence of fetal compromise may be present even in those with stable maternal conditions. Nonreassuring fetal testing may be secondary to maternal acidosis and/or reduced uteroplacental blood flow. [1] [2] [3] [4] [5] [6] The presence of maternal acidosis may be reflected in reducedto-absent fetal movement, absent fetal breathing, or tone during biophysical profile testing. 1 The next step in management is to confirm or exclude the diagnosis of AFLP according to the clinical findings and results of blood tests. 1, 23 The presence of bleeding and/or severe coagulopathy requires transfusion with fresh frozen plasma and other blood products as needed. The ultimate treatment for this condition is maternal stabilization and delivery because there are no reports of women recovering from AFLP spontaneously. The presence of AFLP is not an indication for delivery by cesarean section because of the risks of bleeding complications in the presence of coagulopathy. [2] [3] [4] [5] [6] 10 The decision to perform cesarean delivery should be based on fetal gestational age, fetal condition, and presence of labor. Induction of labor with an attempt for vaginal delivery within 24 hours is a reasonable approach. Because of the associated coagulopathy, most anesthesiologists will avoid epidural analgesia. Maternal analgesia during labor can be provided by intermittent use of small doses of systemic opioids. The use of pudendal block should be avoided because of the risk of bleeding and hematoma formation into this area. Caution should be exercised to avoid vaginal trauma and lacerations during vaginal delivery. 1 In case of cesarean delivery, the patient should receive general anesthesia. It is advisable to avoid incisions that require extensive dissection, such as the Pfannenstiel incision, and meticulous attention should be given to secure hemostasis. It is advisable to perform a midline incision, to use a subfascial drain, and to keep the skin incision open for at least 48 hours to avoid hematoma formation. 1, 23 In the postpartum period, the patient should be monitored very closely with careful evaluation of vital signs, intakeoutput, and bleeding. Some of these patients may develop acute refractory hypotensive shock in the immediate postpartum period. Serial measurements of hematologic, hepatic, and renal function should be performed and recorded in an organized fashion. Blood sugars should be monitored every few hours with a bedside glucometer because of the risk of hypoglycemia in the postpartum period. Glucose infusions can be used to maintain blood sugars above 60 mg/dL. Anemia and DIC should be treated as needed by a packed red blood cells, platelets, and fresh frozen plasma. It is important to aggressively treat maternal hypotension to avoid further injury to the liver, kidneys, and other organs. Invasive hemodynamic monitoring may be necessary in some patients to assess fully the intravascular volumes and maintain cardiac output, and in patients who develop acute respiratory distress syndrome (ARDS).
Pancreatitis is a potentially lethal complication of AFLP, and thus all patients with AFLP should undergo serial screening of serum lipase and amylase for several days after the onset of hepatic dysfunction. 1, 8 Abnormalities in these enzymes typically appear after hepatic and renal dysfunction. The development of pseudocysts with secondary infections or hemorrhagic pancreatitis with resultant retroperitoneal bleeding increases the risk for maternal death. 8 In general, most patients with AFLP will start to improve 2-3 days after delivery. In some cases, however, deterioration in liver function tests, renal function, mental status, and coagulopathy may continue for about 1 week. In such cases, some authors suggest using plasmapheresis to improve maternal outcome. This method of treatment was recently reported in six such cases with no maternal death. However, the value of such therapy remains unclear. In rare cases, a patient will progress into fulminant hepatic failure, requiring liver transplantation. 21 
Counseling of Women with AFLP
Several case reports and case series [22] [23] [24] [25] [26] have noted an association between the development of AFLP and/or HELLP syndrome and a deficiency of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) in infants born to women with the above complications. This disorder of mitochondrial fatty acid oxidation might lead to significant increase in maternal fatty acid levels that are highly toxic to the liver. Based on these findings, some authors suggest that women with AFLP as well as their partners and children should undergo molecular testing for Glu 474 Gln mutation in the LCHAD. 22, 24 Screening for this mutation would allow early diagnosis and treatment in newborns of affected mothers and would allow counseling about subsequent pregnancies. 22, 25 The risk of recurrence is increased in women who are carriers for this mutation, particularly if the fetus is also affected during a subsequent pregnancy. There are few case reports describing recurrent AFLP in women without the above mutation 2, 4 ; however, the risk of this recurrence remains unknown because of the limited number of pregnancies reported following AFLP in these women.
Thrombotic Microangiopathies
Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are two microangiopathic disorders that are extremely rare during pregnancy/postpartum. They are usually reported as case reports or small case series. 1, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Thus, their expected development during preg-nancy or postpartum is probably Ͻ1 case in 100,000 pregnancies. Because of that, they are even infrequent in referral tertiary perinatal centers. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The underlying pathological disturbance involves systemic or intrarenal aggregation of platelets within the arterioles and capillaries in association with endothelial cell injury. In patients with TTP, high levels of endothelial membrane protein thrombomodulin as well as large multimers of von Willebrand factor (VWF) are found in maternal serum. 36, 37 These abnormal molecules cause microvascular platelet aggregates in various organs with resultant thrombocytopenia and mechanical injury to erythrocytes. This latter process results in microangiopathic hemolytic anemia. [36] [37] [38] Most multimers of VWF in the plasma originate from the endothelial cells, but they also can be produced by platelets. 36 A VWF-cleaving metalloprotease (ADAMTS13) in plasma normally prevents the entrance into the circulation (or persistence) of unusually large multimers. 36 This enzyme is produced mainly by hepatocytes, and it degrades these multimers by cleavage to peptide bonds directly on the surface of endothelial cells. 36 In most patients with acquired TTP, plasma ADAMTS13 activity is markedly reduced (Ͻ5% of normal). 39 This reduction of activity of ADAMTS13 prevents timely cleavage of large multimers of VWF as they are secreted by endothelial cells. Consequently, the uncleaved multimers induce adhesion and aggregation of platelets in the microcirculation. [36] [37] [38] [39] Unlike the findings in TTP, the levels of ultralarge VWF multimers are generally not elevated in patients with HELLP syndrome. 40, 41 However, one study found that the amount of active VWF was significantly increased in patients with HELLP syndrome compared with the amount measured in healthy pregnant women and in those with pre-eclampsia without HELLP syndrome. 42 In the same study, the authors found that ADAMTS 13 activity was lower in patients with HELLP syndrome (74 Ϯ 21%) as compared with the values in patients with normal pregnancies (10.5 Ϯ 15%), but the values in HELLP syndrome were within the normal range (61-142%). 42 In addition, two other studies found that the activity of ADAMTS 13 was reduced, but within normal range, and inactivating autoantibodies against ADAMTS 13 were absent in patients with HELLP syndrome. 41, 43 These findings suggest that measurements of ADAMTS 13 activity and/or of inactivity autoantibodies can distinguish between HELLP syndrome and TTP. [40] [41] [42] [43] The classic clinical pentad of TTP consists of thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, fever, and renal dysfunction. The complete pentad is rarely seen in patients with documented cases of TTP 39 , but 50-75% will have the first three clinical findings. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Anemia and thrombocytopenia are frequently severe. [36] [37] [38] [39] The presenting symptoms may include abdominal pain, nausea, vomiting, gastrointestinal bleeding, epistaxis, petechiae, or purpura. [37] [38] [39] Neurologic abnormalities are often difficult to diagnose and may include transient and recurrent symptoms, such as headache, visual changes, confusion, aphasia, transient paresis, weakness, and seizures. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Fever is present in about 30-40% of cases, and when present, it is usually Ͻ101°F. Renal involvement manifests as hematuria, proteinuria, and renal insufficiency. The urine is usually teacolored, similar to that in patients with HELLP syndrome. In contrast, the urine color in AFLP patients is usually bright yellow (Fig. 2) . Hypertension may be present or absent. In severe cases, the pathological lesion of TTP may involve other organs, such as liver, pancreas, heart, and lungs. 37, 38 The extent of involvement of different systems will lead to different and specific clinical manifestations.
Laboratory findings will reveal thrombocytopenia (platelet count Ͻ100,000/mm 3 , usually Ͻ20,000), severe anemia (hematocrit Ͻ25%), marked elevation in serum levels of lactate dehydrogenase (LDH), and the presence of fragmented erythrocytes (schistocytes, helmet cells). [36] [37] [38] [39] It has been suggested that elevated LDH levels are largely derived from ischemic or necrotic tissue cells as well as ruptured red blood cells. 36 Liver enzymes may be normal or elevated, and coagulation studies are frequently normal. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] HUS is mostly seen in children in association with enteric infections with Escherichia coli that produce Shiga toxin. 36, 37 It is extremely rare during pregnancy, and almost all cases have been described in the postpartum period (within 48 hours to 10 weeks). 1, 29, [44] [45] [46] [47] [48] The microvascular injury mainly affects the kidneys and results from glomerular and arteriolar fibrin thrombi. Patients with HUS present with edema, hypertension, bleeding manifestations, or severe renal failure. 1, 26, 29, 30, [44] [45] [46] [47] [48] Renal involvement is more severe than in other thrombotic microangiopathies. [36] [37] [38] Microscopic hematuria and proteinuria are always present. Acute renal failure is an important feature in the clinical course of the disease, and most patients with HUS in pregnancy or postpartum will be left with some form of residual renal deficit. Laboratory findings are similar to those found in TTP, but they are of less magnitude. However, renal function is always markedly abnormal. 1, 29, 30, [44] [45] [46] [47] [48] Maternal Outcomes in TTP-HUS Maternal mortality and morbidity are usually high in pregnancies complicated by TTP or HUS. Maternal mortality rates were as high as 60% before the use of plasma infusions and plasma exchange. In the cases reviewed by Weiner for the years 1966-1987, the maternal mortality for TTP was 44%, and for HUS it was 55%. 48 However, recent case series report a maternal mortality rate of 0-10%. [31] [32] [33] [34] This improved survival in recent studies is attributable to early detection (prior history of TTP or HUS), inclusion of minor forms of TTP, inclusion of women with probable HELLP syndrome or eclampsia, and to improved therapeutic measures, such as plasma infusion, plasma exchange, or immune suppressive therapy. 26, 33, 34 However, maternal morbidities continue to be high (Table 2) . [27] [28] [29] [30] [31] [32] [33] [34] [35] In general, maternal outcome is usually favorable with very low maternal mortality and morbidities in those known to have TTP/HUS before pregnancy, because these patients receive close observation with serial plasmapheresis or exchange as needed. 1, [26] [27] [28] [29] 33, 34 In contrast, maternal mortality and morbidities are usually high in those who develop the manifestations for the first time during pregnancy and/or postpartum. 1, 26, 29, 35 In such cases, there is a delay in confirming the diagnosis because of confusion with HELLP syndrome and other medical conditions. As a result, plasmapheresis is usually initiated late in the disease process. 26, 35 Perinatal Outcome in TTP-HUS In the review by Weiner, 48 the fetal loss rate was 80%. However, recent case series reported a fetal loss rate of 20%. Most cases of TTP develop antepartum with average gestational age at diagnosis of 26 weeks. Therefore, preterm delivery is common. These pregnancies are also associated with reduced uteroplacental blood flow secondary to maternal hypoxia or vascular lesions in the placenta. 43, 49 Perinatal outcome reported in recent series is summarized in Table 3 . [27] [28] [29] [30] [31] [32] [33] [34] [35] 
Management of TTP/HUS
Patients with TTP/HUS should be managed in consultation with a hematologist and/or a nephrologist. Plasma transfusions and exchanges have revolutionized the treatment of these syndromes. Fresh frozen plasma (platelet-poor), cryoprecipitate-poor plasma (cryosupernatant), and plasma treated with a mixture of solvent and detergent all contain the needed deficient metalloprotease. [41] [42] [43] Plasma exchange will help remove unusually large multimers of VWF and autoantibodies against the metalloprotease (ADAMTS13). [41] [42] [43] This therapy is usually effective in approximately 90% of cases. Plasma infusion alone has a response rate of 64%. Treatment should be initiated soon after the diagnosis is made. A response manifested by an increase in platelet count and reduction in LDH levels is expected within a few days of initiating therapy. Plasma exchanges should be performed daily until the platelet count becomes normal and hemolysis resolves, as evident by decrease in LDH levels. 42, 43 Some patients with TTP and high antibody titers against ADAMTS may not respond to plasma exchange alone. These patients require immunosuppressive therapy and/or splenectomy. 37, 41, 42 Platelet transfusions should be avoided if possible, given the potential for increased microvascular thrombosis. Because severe hemorrhage can occur with TTP, it is reasonable to transfuse platelets when there is the potential for life-threatening bleeding. 37 Red cell transfusion should be used according to clinical need. 38, 39 Furthermore, immunosuppressive agents with steroids, cyclophosphamide, vincristine, or rituximab may be needed in patients who develop exacerbations or relapse after plasma exchange is stopped. 37, 41, 42 The treatment of HUS is similar to that of TTP. However, the response to plasma infusions is not as favorable, and most patients will require dialysis.
Delivery is the only cure for patients with HELLP syndrome or AFLP. In contrast, pregnancy should be continued in patients with TTP or HUS who develop the condition remote from term in the absence of fetal compromise and in those who respond to plasma infusions and/or plasma exchange. In rare cases, plasmapheresis results in improvements in fetal heart rate tracing. 50 However, theses patients require close observation of laboratory and clinical findings because of the risk of relapse. Some of the managements used in such patients have included corticosteroids, antiplatelet agents, weekly plasma infusions, and serial plasma exchange or dialysis. 1, 26, [33] [34] [35] 
Counseling of Women with TTP
Women who develop TTP during pregnancy should be aware of the potential of relapse after delivery as well as of risk of relapse in subsequent pregnancies. 28, 30, 32, 34, 35, 38 Therefore, these women should be instructed about the symptoms of early relapse and to report these symptoms immediately. There are few case reports describing recurrent TTP/HUS in subsequent pregnancies 28, 32, 34, 35, 38 ; however, the risk of this recurrence remains unknown because of limited data.
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disorder that is characterized by deposits of antigen-antibody complexes in capillaries and various visceral structures. Most patients are female and of reproductive age (26-40 years old). 51 The clinical findings may be mild or severe amd may affect multiple organ systems, including the kidneys (nephritis), lungs (pleuritis or pneumonitis), liver (hepatitis), and brain. [51] [52] [53] [54] [55] [56] [57] [58] [59] In patients with lupus nephritis, the clinical and laboratory findings are similar to those of severe pre-eclampsia. [51] [52] [53] [54] [55] [56] [57] Such patients will have hypertension, proteinuria, and microscopic hematuria. In some of these women, particularly during an acute exacerbation, patients will have thrombocytopenia. The thrombocytopenia is usually mild to moderate (Ͼ50,000/mm 3 ). [51] [52] [53] [54] [55] [56] [57] [58] [59] Most patients with lupus have skin lesions (typical discoid or malar rash), and joint symptoms and fever are very common during an acute flare.
During the active phase of SLE exacerbation, laboratory findings will show pancytopenia, thrombocytopenia, hemolytic anemia, and an increase in anti-DNA antibodies. Serum complement levels may be normal or depressed. Severe lupus flares occur in 25-30%, and it may develop for the first time during pregnancy or in the postpartum period. 51, 55 In patients with lupus nephritis who develop active flare during pregnancy, the clinical and laboratory findings are similar to those with severe pre-eclampsia and HELLP syndrome. [53] [54] [55] [56] 58 The exact diagnosis may be difficult, particularly in those with associated antiphospholipid antibodies (APAs). [58] [59] [60] [61] [62] [63] APAs (lupus anticoagulant and/or anticardiolipin antibodies) are present in 30-40% of patients with systemic lupus. [59] [60] [61] These patients are at increased risk for thrombotic events. Patients with lupus and APA are at risk for tissue ischemia secondary to thromboembolic events and thrombotic microangiopathy, resulting in a clinical picture similar to that seen in HELLP syndrome, eclampsia, TTP, and HUS. [61] [62] [63] [64] [65] [66] [67] Thrombocytopenia is seen in about 40-50% of these cases and hemolytic anemia in 14-23%. 61 Cerebral lesions and symptoms will develop because of cerebral vasculitis and/or cerebral vaso-occlusive disease. In such patients, the clinical and laboratory findings are similar to those with eclampsia. 61 In patients with renal involvement, hypertension and proteinuria are the rule with findings identical to severe pre-eclampsia.
The catastrophic antiphospholipid syndrome occurs in Ͻ1% of patients with APA syndrome. 60 It is characterized by acute thrombotic microangiopathy affecting small vessels of multiple organs (at least three). The most common affected organs are the kidneys and central nervous system. 60, 61 Liver involvement will result in cellular necrosis and infarcts, leading to elevated liver enzymes. [64] [65] [66] The clinical and laboratory findings may also be similar to other microvascular angiopathies. [60] [61] [62] [63] [64] [65] [66] [67] 
Maternal-Perinatal Outcome
Pregnancy outcome is usually favorable in patients with SLE who were in remission before pregnancy and who do not develop a flare during pregnancy. 51, 57 In addition, the outcome is favorable in those without lupus nephritis and/or absent antiphospholipid antibodies. 52, [55] [56] [57] However, maternal morbidities and perinatal mortality and morbidity are increased in those with lupus nephritis central nervous system disease and in those with antiphospholipid antibodies. [51] [52] [53] [54] [55] [59] [60] [61] [62] These latter pregnancies are associated with high rates of miscarriage, fetal death (4-19%), intrauterine growth restriction, and preterm delivery (38-54%). This high rate of fetal loss and perinatal complications is related to decidual vascular thrombosis and placental infarctions and hemorrhage. [59] [60] [61] [62] Maternal complications include a high rate of early onset pre-eclampsia and complications related to thromboembolism and microangiopathy. [57] [58] [59] [60] [61] Maternal morbidities are substantially increased in those with APA syndrome. [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Maternal mortality is almost 50% in patients who develop the catastrophic APA syndrome. 61 
Management
Management of SLE flare during pregnancy will depend on the presence of the organ systems involved, laboratory findings (thrombocytopenia, APAs), and the presence or absence of nephritis. Treatment usually includes the use of corticosteroids, low-dose aspirin, hydroxychloroquine immunosuppressive drugs, and heparin. [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] The usual dose of steroids is 40-80 mg/day of prednisone, and for aspirin it is 81 mg/day. Prednisone therapy is usually used in patients with lupus nephritis, whereas combined regimens of prednisone and low-dose aspirin are recommended in patients with APAs. [59] [60] [61] 68 Alternative regimens have included the use of heparin plus low-dose aspirin. For patients with severe thrombocytopenia that does not respond to the above regimens, intravenous ␥ globulin may be beneficial. 61 Recent data also suggested that the use of other agents, such as azathioprine, cyclosporin, and hydroxychloroquine, may be required in management of some of these patients. 54, 59, 68 In patients with catastrophic APA syndrome, treatment includes full anticoagulation with heparin, steroids, plus plasmapheresis. 60, 61, 66 In summary, the clinical presentations of AFLP, TTP, HUS, and exacerbation of SLE can be easily confused with those of severe pre-eclampsia-eclampsia HELLP syndrome. Although these conditions share a range of signs and symptoms (Table 4 ) and laboratory tests (Table 5 ) with HELLP syndrome, each has some distinguishing clinical findings or laboratory results. Making the right diagnosis is extremely important regarding decisions about need for delivery as well as treatment and complications.
Systemic Viral Sepsis
Disseminated herpes simplex is a rare complication during pregnancy. It is usually seen in immunocompromised pregnant women. The onset is usually in the third trimester (average onset of 30 weeks) with clinical presentation of fever, abdominal pain, and upper respiratory symptoms. [69] [70] [71] [72] Some patients will have hepatitis without jaundice and encephalitis. 69, 71, 72 Hepatitis is a common finding in fulminant sepsis. 70, 72 Hypertension and proteinuria are absent. Laboratory findings will reveal leukopenia, thrombocytopenia, hemolysis, DIC, markedly elevated levels of AST (Ͼ2000 IU/L), and severe elevations in LDH levels. In fulminant cases, the ammonia levels may be elevated; however, bilirubin values are usually normal or slightly elevated, which is different from the usual finding in patients with AFLP. The diagnosis is usually made in the presence of vesicular lesions in the skin, perineum, or the cervix. Liver biopsy will show the typical intranuclear inclusions (Cowdry type A inclusions) with association with cell necrosis and hemorrhage (Fig. 2) . The CT scan may show the typical mottled appearance in the liver (multiple low-density areas that do not enhance with contrast injection), which is different from the CT scan findings in patients with HELLP syndrome, AFLP, or liver infarction. 1 Disseminated herpes infection is associated with high maternal and perinatal mortality if not treated promptly. [69] [70] [71] [72] In a review of 24 cases of herpes simplex hepatitis in pregnancy up to the year 1998, Kanga and Graves 70 found an overall maternal mortality of 39% and perinatal mortality of 39%. Maternal mortality was 0% among 13 women treated with acyclovir and 20% among 4 women treated with vidarabine, whereas it was 67% among 15 women receiving no antiviral therapy. 70 In addition, the perinatal mortality was 18% in those receiving acyclovir, 67% among those receiving vidarabine, and 44% among those receiving no therapy. Therefore, accurate and urgent diagnosis is important because early therapy with acyclovir improves survival. The usual dose of intravenous acyclovir is 10-15 mg/kg of body weight every 8 hours to be continued for at least 10 days. [69] [70] [71] [72] These patients should be managed in an intensive care facility. There is no need for early delivery in the absence of fetal indications. 70 
Systemic

Inflammatory Response Syndrome (SIRS)/Septic Shock
SIRS describes a systemic inflammatory process that can be generated by infection or by noninfectious causes, such as pancreatitis, burns, and major trauma. [73] [74] [75] [76] [77] [78] It is characterized by a hyperdynamic state, endothelial cell injury, leukocytosis, neutrophil activation, and tissue hypoperfusion with multiorgan dysfunction. 71, [73] [74] [75] [76] [77] [78] Sepsis is SIRS due to infection that is associated with hypoperfusion or hypotension with organ dysfunction. Septic shock is a subset of sepsis defined as sepsis-induced hypotension despite adequate fluid resuscitation along with the presence of perfusion abnormalities, such as lactic acidosis, renal dysfunction (oliguria, acute tubular necrosis), hepatic dysfunction, and acute changes in mental status. [73] [74] [75] [76] [77] [78] Laboratory findings include leukocytosis or leukopenia (white blood count Ͻ4000), thrombocytopenia, hemolysis, DIC, elevated liver enzymes, and elevated bilirubin.
Some authors suggested that the maternal syndrome of pre-eclampsia share many of the clinical and laboratory findings of patients with SIRS. 79, 80 Both syndromes are characterized by systemic inflammation, neutrophilia, and neutrophil activation. Indeed, many of the clinical and laboratory findings of women with HELLP syndrome, such as hemolysis, hepatocellular necrosis, renal dysfunction, pulmonary edema, ARDS, and thrombocytopenia, are similar to those seen in patients with severe sepsis and septic shock. 79, 80 A recent report by Afessa and coworkers 74 found that 59% of obstetric patients admitted to ICU developed SIRS.
In general, patients with severe sepsis or septic shock will have fever, but hypertension and proteinuria are absent. However, hypertension or proteinuria may be absent in 10-15% of patients with HELLP syndrome. In addition, leukocytosis and fever may be present in women with pre-eclampsia because of endomyometritis, particularly after cesarean delivery. Table 1 compares clinical and laboratory findings between those with disseminated herpes and SIRS/sepsis in pregnancy. Septic shock is rare during pregnancy or postpartum. [73] [74] [75] [76] It should be considered in the differential diagnosis of patients with fever, microangiopathic hemolysis, thrombocytopenia, renal insufficiency, altered mental status, and pulmonary insufficiency. The clinical picture can mimic HELLP syndrome, AFLP, TTP and HUS, and an SLE flare. It can be the primary cause or it can be a complication of any one of the above syndromes. The clinical findings include a temperature Ͼ38°C or Ͻ36°C, tachycardia (pulse Ͼ100 bpm), tachypnea (respiratory rate Ͼ24/min), and hypotension (systolic blood pressure Ͻ90 mm Hg). Cardiac output is initially elevated, systemic vascular resistance is low, and venous return is reduced. With reduced tissue perfusion, oxygen delivery is impaired, resulting in increased lactate levels secondary to anerobic cellular metabolism. Both hypotension and poor tissue perfusion will ultimately lead to multiple organ failure. [73] [74] [75] [76] [77] [78] 
Maternal and Perinatal Outcome in Septic Shock
Mabie and coworkers 73 reported the etiology, management, and outcome in 18 patients with septic shock during pregnancy. The etiology of shock were pyelonephritis in 6 women, chorioamnionitis in 3, postpartum endometritis in 3, toxic shock syndrome in 2, and 1 each of septic abortion, appendicitis, ovarian abscess, necrotizing fasciitis, and bacterial endocarditis. Five women (28%) died, and 15 (82%) had multiorgan dysfunction. The perinatal survival was 50% (10 of 20, one set of triplets). Five of the 10 losses were Յ20 weeks' gestation, and 5 were stillbirths. 73 Afessa and coworkers 74 reported on 44 obstetric patients who developed SIRS; 2 patients had septic shock and 18 had severe sepsis. Two women (4.5%) died, and 36 (82%) had multiorgan failure.
Management of Septic Shock
Treatment of septic shock consists of resuscitation with fluids, vasopressors, antibiotics, hemodynamic monitoring, removal of source of infection (surgery or percutaneous drainage of abscesses), and modifying of inflammatory mediators.
Patients with SIRS or septic shock require admission to an intensive care unit to monitor volume replacement with crystalloids or blood components, to monitor vital signs, urine output, oxygenation, and mental status. [73] [74] [75] [76] [77] [78] Fluid resuscitation will include 3-4 L of crystalloid over 60 minutes, to correct hypotension and to achieve a central venous pressure of 8-12 mm Hg. If hypotension persists, then vasoactive agents are used. The first drug of choice is dopamine, titrated up to 20 mg/kg/min to achieve a MAP of at least 65 mm Hg (MAP needed to keep adequate tissue perfusion, particularly cerebral perfusion). [73] [74] [75] [76] [77] [78] Other vasoactive drugs, such as dobutamine or norepinephrine, can be used as needed. If the patient does not show good response to broad spectrum antibiotic therapy, attention should be given to identify a source of infection (retained products of conception, microabscesses in uterine wall, pelvic abscess, etc.) that require surgical intervention. 71, [73] [74] [75] [76] In general, delivery is required if there is evidence of an infected fetus, amniotic fluid, or placental tissues. On the other hand, delivery is not indicated in the absence of infection in the uterine cavity. A detailed descrip-tion of pathophysiology and management of sepsis has been described. [76] [77] [78] [79] [80] 
Conclusions
Several microangiopathic disorders can occur any time during pregnancy or during the postpartum period. The incidence of these disorders is extremely low; however, the maternal and perinatal complications are extremely high. The clinical presentation and laboratory findings in these disorders can mimic those seen in pre-eclampsia and eclampsia. Consequently, there is the potential for delay in diagnosis and treatment during management of these women. Therefore, it is important that managing physicians be aware of the etiology, diagnostic findings, and management of such disorders. Finally, a rapid diagnosis and close consultation with an interdisciplinary team of physicians, such as maternalfetal medicine, nephrologist, hematologist, critical care, etc., may result in optimal outcome for the mother and fetus. 12 
Box I Imitators of
